Perphenazine is indicated for use in the management of the manifestations of psychotic disorders; and for the control of severe nausea and vomiting in adults.

Perphenazine has not been shown effective in the management of behavoral complications in patients with mental retardation.

Dosage must be individualized and adjusted according to the severity of the condition and the response obtained. As with all potent drugs, the best dose is the lowest dose that will produce the desired clinical effect. Since extrapyramidal symptoms increase in frequency and severity with increased dosage, it is important to employ the lowest effective dose. These symptoms have disappeared upon reduction of dosage, withdrawal of the drug, or administration of an antiparkinsonian agent.

Prolonged administration of doses exceeding 24 mg daily should be reserved for hospitalized patients or patients under continued observation for early detection and management of adverse reactions. An antiparkinsonian agent, such as trihexyphenidyl hydrochloride or benztropine mesylate, is valuable in controlling drug-induced extrapyramidal symptoms.

Suggested dosages for various conditions follow:

Moderately disturbed nonhospitalized psychotic patients: 4 to 8 mg t.i.d. initially; reduce as soon as possible to minimum effective dosage.

Hospitalized psychotic patients: 8 to 16 mg b.i.d. to q.i.d.; avoid dosages in excess of 64 mg daily.

Severe nausea and vomiting in adults: 8 to 16 mg daily in divided doses; 24 mg occasionally may be necessary; early dosage reduction is desirable.

Perphenazine tablets, USP are supplied as:

2 mg: round, unscored, film-coated white tablets, debossed GG18 on one side and plain on the reverse side, in bottles of 100 and 1000, and in unit dose packages of 100.

4 mg: round, unscored, film-coated white tablets, debossed GG107 on one side and plain on the reverse side, in bottles of 100, 500 and 1000, and in unit dose packages of 100.

8 mg: round, unscored, film-coated white tablets, debossed GG108 on one side and plain on the reverse side, in bottles of 100, 500 and 1000, and in unit dose packages of 100.

16 mg: round, unscored, film-coated white tablets, debossed GG 109 on one side and plain on the reverse side, in bottles of 100 and 1000, and in unit dose packages of 100.

Store at controlled room temperature 150-300C (590-860F). Dispense in a tight, light-resistant container.

Manufactured By
Geneva Pharmaceuticals, Inc.
Broomfield, CO 80020
FOR:
Schering Corporation 504
Kenilworth, NJ 07033 USA

Bookmark this page: